尿路上皮癌的精准医学和预测医学：我们是否取得进展？
Precision and predictive medicine in urothelial cancer: are we making progress?
机构信息
Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
出版信息
Eur Urol. 2015 Oct;68(4):547-9. doi: 10.1016/j.eururo.2015.04.025. Epub 2015 Apr 29.
PMID:25935702
Abstract
Therapy for urothelial carcinoma appears poised for a breakthrough on the basis of information regarding molecular subtypes and promising activity of PD-1/PD-L1 inhibitors. Precision medicine may be possible using rational marker-driven trial designs with enriched information from tumor genotyping and extreme responders.
摘要
基于关于分子亚型的信息和 PD-1/PD-L1 抑制剂的有前景的活性，尿路上皮癌的治疗似乎即将取得突破。使用基于合理标志物的试验设计，从肿瘤基因分型和极端应答者中获取丰富的信息，可能实现精准医疗。
Zotero 插件